Learn more →
Back to Expert Scholars
clinical / clinicalOvarian Cancer Advanced 2026

Felix Hilpert

菲利克斯·希尔珀特

MD, PhD

🏢Krankenhaus Jerusalem Hamburg(汉堡耶路撒冷医院)🌐Germany

Director, Gynecological Oncology妇科肿瘤学主任

39
h-index
2
Key Papers
3
Awards
2
Key Contributions

👥Biography 个人简介

Felix Hilpert is Director of Gynecological Oncology at Krankenhaus Jerusalem Hamburg and an internationally recognized surgical oncologist specializing in advanced ovarian cancer. He was the principal investigator of the landmark LION trial (Lymphadenectomy in Ovarian Neoplasms), which definitively demonstrated that systematic pelvic and para-aortic lymphadenectomy does not improve survival in women with advanced ovarian cancer achieving complete macroscopic resection, published in NEJM 2019.

Share:

🧪Research Fields 研究领域

Ovarian Cancer Surgery卵巢癌手术
LION Trial LymphadenectomyLION试验淋巴结清扫
Cytoreductive Surgery减瘤手术
AGO-OVAR TrialsAGO-OVAR试验
Debulking Surgery肿瘤切除手术
Surgical Quality in Ovarian Cancer卵巢癌手术质量

🎓Key Contributions 主要贡献

LION Trial: Lymphadenectomy in Advanced Ovarian Cancer

PI of the LION phase III RCT, demonstrating that systematic lymphadenectomy did not improve overall or progression-free survival vs no lymphadenectomy in advanced ovarian cancer with complete cytoreduction, fundamentally changing surgical practice guidelines worldwide.

Cytoreductive Surgery Quality Standards in Ovarian Cancer

Contributed to AGO-OVAR surgical quality initiatives, defining standards for complete cytoreduction and metrics for surgical excellence in advanced ovarian cancer, and investigating the prognostic impact of residual disease status after primary surgery.

Representative Works 代表性著作

[1]

Lymphadenectomy in Patients with Advanced Ovarian Neoplasms (LION)

New England Journal of Medicine (2019)

Phase III RCT demonstrating systematic lymphadenectomy did not improve survival outcomes in optimally debulked advanced ovarian cancer, removing routine lymphadenectomy from surgical standards.

[2]

Prognostic Value of Residual Disease Status After Primary Cytoreductive Surgery in Advanced Ovarian Cancer

Annals of Surgical Oncology (2021)

Confirmed complete macroscopic cytoreduction as the critical surgical endpoint associated with prolonged survival in advanced ovarian cancer across AGO-OVAR cohorts.

🏆Awards & Recognition 奖项与荣誉

🏆AGO-OVAR Surgical Research Award
🏆Deutsche Gesellschaft für Gynäkologie und Geburtshilfe Scientific Prize
🏆ESGO Award for Surgical Excellence

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 菲利克斯·希尔珀特 的研究动态

Follow Felix Hilpert's research updates

留下邮箱,当我们发布与 Felix Hilpert(Krankenhaus Jerusalem Hamburg)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment